EHA 2016 | Treatment options for co-morbid CLL patients
Barbara Eichhorst
• 9 Jun 2016
Barbara Eichhorst, MD from University of Cologne, Cologne, Germany discusses treatment options for co-morbid chronic lymphocytic leukemia (CLL) patients. These individuals face frequent medical problems which have to be taken into consideration when choosing a treatment regimen. Dosage reduced treatment should be considered as an option, for example fludarabine plus cyclophosphamide plus rituximab. Another combination that has shown promising responses is bendamustine plus rituximab. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
